Erratum to Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus

The third sentence in the first paragraph of the Pharmacological Properties Summary should read, 'The beneficial effects of acarbose on postprandial glucose levels have been confirmed in patients with insulin-dependent or non-insulin-dependent diabetes mellitus (IDDM or NIDDM), and postprandial insulin and triglyceride levels were also lowered.' page 1027: The second sentence of paragraph 2 of the Tolerability Summary should read, 'However, analysis of data from phase III US studies indicated that anaemia and elevated transaminase levels were significantly more common in patients receiving acarbose (at a dosage greater than the maximum currently recommended) than in placebo recipients.' page 1028: The fourth sentence in the first paragraph of the Dosage and Administration Summary should read: 'Contraindications to acarbose use include age less than 12 years, inflammatory bowel disease ... '. page 1047: The following sentence should be added at the end of the fourth paragraph of section 3.2 Systemic Effects: 'Furthermore, patients in these trials received acarbose at a dosage greater than the maximum currently recommended.'page 1048: The first sentence in the third paragraph of section 5 Dosage and Administration should read: 'Acarbose is contraindicated in children aged less than 12 years, and in patients with inflammatory bowel disease ... '. [